ABCB1/MDR1 Gene: P-Glycoprotein and Why Medication Doses Vary by Genetics

You and a friend take the same antidepressant at the same dose. One of you feels a clear effect within two weeks. The other feels almost nothing for months. One reason this happens — an underappreciated one — is a gene called ABCB1, which controls how much of the drug actually reaches your brain.

What P-Glycoprotein Does

P-glycoprotein (P-gp) is an efflux transporter — a molecular pump that actively moves substances out of cells and back into the bloodstream or gut lumen. It is concentrated at critical biological barriers: the blood-brain barrier, the intestinal wall, the liver, and the kidneys.

Its original job is protection. P-gp evolved to remove toxic compounds before they accumulate in sensitive tissues. But it cannot distinguish between a toxin and a medication. Drugs that are P-gp substrates get pumped out right alongside genuine toxins — reducing how much reaches the target organ.

The C3435T variant in ABCB1 affects P-gp expression and activity. TT carriers have lower P-gp activity, meaning drugs linger longer in cells. CC carriers pump drugs out more efficiently, potentially requiring higher doses to achieve the same effect.

Which Medications Are Affected

The list of P-gp substrates is extensive. Major categories include:

What This Means Practically

For most people, ABCB1 genotype is one factor among many in medication response — not a deterministic override. But it helps explain why dose titration is necessary, why some people respond to lower doses, and why treatment-resistant cases sometimes turn out to be pharmacokinetic rather than pharmacodynamic problems.

The most clinically relevant application is in psychiatry, where P-gp activity at the blood-brain barrier directly controls how much antidepressant or antipsychotic reaches neurons. TT carriers with lower P-gp activity may experience stronger effects at lower doses and a higher risk of side effects at standard doses. CC carriers may need higher doses to achieve therapeutic levels in brain tissue.